🇺🇸 FDA
Patent

US 9624306

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 9624306 (Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/47